Abstract 400P
Background
Long non-coding RNAs (LncRNAs) play a critical part in tumor growth and metastasis, but only a small number of LncRNAs are functionally annotated.
Methods
The GEO database was used to analyze breast cancer-related transcriptome data and identify the differentially expressed LncRNA-LINC00294, and qRT-PCR was used to validate the expression of LINC00294 in 30 pairs of breast and para cancer tissues, as well as normal human breast epithelial cells MCF-10A and breast cancer cells MDA-MB-231, SK-BR-3, and MCF-7. The influence of LINC00294 overexpression/interference on the biological properties of breast cancer cells was validated using Western Blot, Transwell, scratch assay, flow cytometry, and CCK-8; the infection of LINC00294 overexpression on the growth of breast tumors in vivo was validated using an in situ tumorigenesis assay in nude mice; the effects of LINC00294 overexpression on the growth of breast tumors in vivo were inquired using Western Blot. The infection of LINC00294 in breast cancer cell biology was investigated by Western Blot, Transwell, scratch assay, and luciferase reporter to investigate the mechanism by which LINC00294 affects breast cancer development via ceRNA adsorption and thus regulates JUP expression.
Results
LINC00294 was significantly upregulated in breast cancer tissues. Furthermore, interference with LINC00294 significantly inhibited breast cancer cell multiplication, invasion, and migration, while overexpression of LINC00294 promoted breast cancer cell invasion proliferation, proliferation, and migration, as well as tumor growth. According to mechanistic studies, LINC00294 could regulate JUP expression and thus the Wnt/β-catenin signaling pathway by targeting miR-485-5p, thus affecting the development of breast cancer.
Conclusions
LINC00294 is highly expressed in breast cancer and may spaciously adsorb miR-485-5p through the ceRNA mechanism to regulate JUP expression, which in turn regulates the Wnt/β-catenin signaling pathway and affects the development of breast cancer. Our findings show that LINC00294 has an effect on breast cancer and identifies a new possible prognostic marker and therapeutic target for this disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
the 'Kuanren meritocrat'Backbone Talents Project of The Second Affiliated Hospital of Chongqing Medical University (no. KY2019G016), Wu Jiping Medical Foundation (no.320.6750.2021-10-86) and Natural Science Foundation of Chongqing, China(no.CSTB2022NSCQ-MSX0055).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
425P - The humanitarian PACT for advanced breast cancer: A multi-stakeholder collaboration to improve access to treatment in low- and middle-income countries
Presenter: Alicia Annamalay
Session: Poster session 15
426P - Impact of statin therapy on mortality and recurrence in female breast cancer: A meta-analysis
Presenter: Maria Eduarda Souza
Session: Poster session 15
427P - The role of patient navigation (PN) in delivering goal-concordant care to advanced breast cancer (ABC) patients
Presenter: Akshara Singareeka Raghavendra
Session: Poster session 15
428P - Key landmarks of male advanced breast cancer: Results of the GEICAM/2016-04 study
Presenter: Noelia Martinez
Session: Poster session 15
429P - Brain imaging screening (BIS) in metastatic breast cancer (MBC): Patients’ and physicians’ perspectives
Presenter: Ana Leonor Matos
Session: Poster session 15
430P - A novel survival predicting model for breast cancer brain metastasis based on multimodal data
Presenter: Zisheng Wu
Session: Poster session 15
431P - Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the TROPION-Breast01 study of datopotamab deruxtecan (Dato-DXd) vs investigator’s choice of chemotherapy (ICC) in patients (pts) with pretreated, inoperable/metastatic HR+/HER2– breast cancer (BC)
Presenter: Hope Rugo
Session: Poster session 15
432P - Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physician’s choice in HER2-low, hormone receptor–positive metastatic breast cancer in DESTINY-Breast04
Presenter: Naoto Ueno
Session: Poster session 15
433TiP - Phase III, randomized, open-label TroFuse-010 Study of sacituzumab tirumotecan (sac-TMT) alone and with pembrolizumab vs treatment of physician’s choice chemotherapy (TPC) in patients with HR+/HER2- unresectable locally advanced or metastatic breast cancer (mBC)
Presenter: Sara Tolaney
Session: Poster session 15
434TiP - ALTER-BC-Ib-01: A prospective phase Ib study of anlotinib with trastuzumab deruxtecan (T-DXd) for HER2-low unresectable (u)/metastatic (m) breast cancer (BC)
Presenter: Yanchun Meng
Session: Poster session 15